Quince Therapeutics, Inc. Severance Costs
Quince Therapeutics, Inc. (QNCX) reported Severance Costs of $300.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2025-03-24
- Quince Therapeutics, Inc. severance costs for the quarter ending 2024-03-31 was $300.00K, a 0.00% change year-over-year.
- Quince Therapeutics, Inc. severance costs for the quarter ending 2023-04-30 was $300.00K, a 14.94% increase year-over-year.
- Quince Therapeutics, Inc. severance costs for the quarter ending 2022-06-30 was $412.00K.
- Quince Therapeutics, Inc. severance costs for the quarter ending 2022-03-31 was $261.00K.
- Quince Therapeutics, Inc. severance costs for fiscal 2023 was $300.00K.
| Period end | Severance Costs | Severance Costs as first filed | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $300.00K 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $300.00K 10-K · filed 2024-04-01 | ||||
| 2023-08-04 | $500.00K 10-K · filed 2025-03-24 | $475.00M 10-Q · filed 2023-11-14 | |||
| 2023-04-30 | $300.00K 10-K · filed 2025-03-24 | ||||
| 2022-07-22 | $339.00M 10-Q · filed 2022-08-09 | ||||
| 2022-06-30 | $412.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $673.00K 10-Q · filed 2022-08-09 | |||
| 2022-06-08 | $354.75M 10-Q · filed 2022-08-09 | ||||
| 2022-05-19 | $339.00M 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $261.00K 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |